BIOYF
Price
$8.66
Change
-$0.06 (-0.69%)
Updated
Sep 3 closing price
Capitalization
96.57M
BUDZ
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Sep 4 closing price
Capitalization
6.09M
Interact to see
Advertisement

BIOYF vs BUDZ

Header iconBIOYF vs BUDZ Comparison
Open Charts BIOYF vs BUDZBanner chart's image
BioSyent
Price$8.66
Change-$0.06 (-0.69%)
Volume$755
Capitalization96.57M
WEED
Price$0.04
Change-$0.00 (-0.00%)
Volume$333.24K
Capitalization6.09M
BIOYF vs BUDZ Comparison Chart in %
Loading...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BUDZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIOYF vs. BUDZ commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOYF is a Hold and BUDZ is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (BIOYF: $8.66 vs. BUDZ: $0.04)
Brand notoriety: BIOYF and BUDZ are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOYF: 53% vs. BUDZ: 201%
Market capitalization -- BIOYF: $98.31M vs. BUDZ: $6.04M
BIOYF [@Pharmaceuticals: Generic] is valued at $98.31M. BUDZ’s [@Pharmaceuticals: Generic] market capitalization is $6.04M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.9B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOYF’s FA Score shows that 1 FA rating(s) are green whileBUDZ’s FA Score has 0 green FA rating(s).

  • BIOYF’s FA Score: 1 green, 4 red.
  • BUDZ’s FA Score: 0 green, 5 red.
According to our system of comparison, BIOYF is a better buy in the long-term than BUDZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOYF’s TA Score shows that 7 TA indicator(s) are bullish while BUDZ’s TA Score has 5 bullish TA indicator(s).

  • BIOYF’s TA Score: 7 bullish, 3 bearish.
  • BUDZ’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, BIOYF is a better buy in the short-term than BUDZ.

Price Growth

BIOYF (@Pharmaceuticals: Generic) experienced а -0.00% price change this week, while BUDZ (@Pharmaceuticals: Generic) price change was +26.86% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.24%, and the average quarterly price growth was +86.08%.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOYF($96.6M) has a higher market cap than BUDZ($6.09M). BUDZ has higher P/E ratio than BIOYF: BUDZ (51.57) vs BIOYF (16.59). BUDZ YTD gains are higher at: 38.296 vs. BIOYF (13.314). BIOYF has higher annual earnings (EBITDA): 11.3M vs. BUDZ (-721.28K). BIOYF has more cash in the bank: 17.4M vs. BUDZ (5.35K). BUDZ has less debt than BIOYF: BUDZ (357K) vs BIOYF (990K). BIOYF has higher revenues than BUDZ: BIOYF (38.3M) vs BUDZ (0).
BIOYFBUDZBIOYF / BUDZ
Capitalization96.6M6.09M1,586%
EBITDA11.3M-721.28K-1,567%
Gain YTD13.31438.29635%
P/E Ratio16.5951.5732%
Revenue38.3M0-
Total Cash17.4M5.35K325,234%
Total Debt990K357K277%
FUNDAMENTALS RATINGS
BIOYF vs BUDZ: Fundamental Ratings
BIOYF
BUDZ
OUTLOOK RATING
1..100
213
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
97
Overvalued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
42100
PRICE GROWTH RATING
1..100
5239
P/E GROWTH RATING
1..100
6192
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOYF's Valuation (27) in the null industry is significantly better than the same rating for BUDZ (97). This means that BIOYF’s stock grew significantly faster than BUDZ’s over the last 12 months.

BIOYF's Profit vs Risk Rating (38) in the null industry is somewhat better than the same rating for BUDZ (100). This means that BIOYF’s stock grew somewhat faster than BUDZ’s over the last 12 months.

BIOYF's SMR Rating (42) in the null industry is somewhat better than the same rating for BUDZ (100). This means that BIOYF’s stock grew somewhat faster than BUDZ’s over the last 12 months.

BUDZ's Price Growth Rating (39) in the null industry is in the same range as BIOYF (52). This means that BUDZ’s stock grew similarly to BIOYF’s over the last 12 months.

BIOYF's P/E Growth Rating (61) in the null industry is in the same range as BUDZ (92). This means that BIOYF’s stock grew similarly to BUDZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOYFBUDZ
RSI
ODDS (%)
Bullish Trend 2 days ago
43%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
42%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
43%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
44%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
45%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
44%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 8 days ago
47%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
41%
Bearish Trend 22 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
43%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
40%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BUDZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CAMT78.201.47
+1.92%
Camtek Ltd
DTE136.410.92
+0.68%
DTE Energy Company
PLL7.25N/A
N/A
Piedmont Lithium
WETH1.14-0.04
-3.39%
Wetouch Technology
NAGE9.32-0.35
-3.62%
Niagen Bioscience Inc

BIOYF and

Correlation & Price change

A.I.dvisor tells us that BIOYF and BUDZ have been poorly correlated (+6% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOYF and BUDZ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOYF
1D Price
Change %
BIOYF100%
N/A
BUDZ - BIOYF
6%
Poorly correlated
+17.34%
AVCNF - BIOYF
1%
Poorly correlated
-1.29%
APNHY - BIOYF
0%
Poorly correlated
+0.68%
BSPK - BIOYF
0%
Poorly correlated
N/A
BIOVF - BIOYF
0%
Poorly correlated
-4.52%
More

BUDZ and

Correlation & Price change

A.I.dvisor tells us that BUDZ and CBWTF have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BUDZ and CBWTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BUDZ
1D Price
Change %
BUDZ100%
+17.34%
CBWTF - BUDZ
14%
Poorly correlated
-2.73%
BOIRF - BUDZ
7%
Poorly correlated
N/A
CANN - BUDZ
7%
Poorly correlated
+8.98%
BIOYF - BUDZ
6%
Poorly correlated
N/A
BSPK - BUDZ
2%
Poorly correlated
N/A
More